Here’s Why Eli Lilly and Company (LLY) Surged in Q2
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...
First-of-its-kind Alzheimer's drug offers hope of treatment
Developed by international researchers led by British experts, RI-AG03, tackles two 'hotspots' on the protein that leads to ...
New Report: Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome
WASHINGTON, DC / ACCESSWIRE / October 1, 2024 / Boosting research investment into the health and wellbeing of adults with Down syndrome would ...
technologynetworks4d
The Evolving Treatment Landscape for Alzheimer’s
We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...
Critical Flaws: New Alzheimer’s Drug Could Actually Be a Safety Risk
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
i5d
Alzheimer’s ‘wonder drug’ was recommended by scientists funded by pharma firms
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...